HEPC-based liposomes trigger cytokine release from peripheral blood cells: effects of liposomal size, dose and lipid composition

被引:8
作者
Yamamoto, S
Ishida, T
Inoue, A
Mikami, J
Muraguchi, M
Ohmoto, Y
Kiwada, H [1 ]
机构
[1] Univ Tokushima, Grad Sch Pharmaceut Sci, Fac Pharmaceut Sci, Dept Pharmacokinet & Biopharmaceut, Tokushima 7708505, Japan
[2] Otsuka Pharmaceut Co Ltd, Tokushima 7710192, Japan
关键词
liposome; cytokine; human peripheral blood cell; whole-blood induction; immune system;
D O I
10.1016/S0378-5173(02)00026-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The immune response caused by liposome stimulation was studied by assessing the level of several cytokines released from human peripheral blood cells. Liposome stimulation resulted in the release of IL-6, IL-10, TNF-alpha and IFN-gamma. The size of the liposomes affected the degree of the cytokine releases with larger sized liposomes causing higher levels of cytokine induction. In addition. it appears that the lipid composition of liposomes had no effect on the degree of cytokine release. The release of cytokines occurred even in the absence of serum, suggesting that serum proteins did not contribute to liposome stimulation in peripheral blood cells. The release of cytokines induced by liposome stimulation was inhibited by the presence of either protein kinase-C (PKC) or protein tyrosine kinase (PTK) inhibitor, but not by the presence of an endocytosis inhibitor. This indicates that signal transduction via PKC or PTK is necessary, in order for human peripheral blood cells to release cytokines (IL-6, IL-10, IL-1beta, TNF-alpha and IFN-gamma) as the result of liposome stimulation. These quantitative data on the release of cytokines by liposomal stimulation provide useful information for the development of rational drug delivery systems and the safety of cytokine induction via the use of liposomes. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:125 / 133
页数:9
相关论文
共 25 条
[1]   LIPOPOLYSACCHARIDE, LIPID-A, AND LIPOSOMES CONTAINING LIPID-A AS IMMUNOLOGICAL ADJUVANTS [J].
ALVING, CR .
IMMUNOBIOLOGY, 1993, 187 (3-5) :430-446
[2]   CYTOKINE PRODUCTION AT THE SITE OF DISEASE IN HUMAN TUBERCULOSIS [J].
BARNES, PF ;
LU, SZ ;
ABRAMS, JS ;
WANG, E ;
YAMAMURA, M ;
MODLIN, RL .
INFECTION AND IMMUNITY, 1993, 61 (08) :3482-3489
[3]  
Detmers PA, 1996, J IMMUNOL, V157, P5589
[4]   Identification of the 80-kDa LPS-binding protein (LMP80) as decay-accelerating factor (DAF, CD55) [J].
El-Samalouti, VT ;
Schletter, J ;
Chyla, I ;
Lentschat, A ;
Mamat, U ;
Brade, L ;
Flad, HD ;
Ulmer, AJ ;
Hamann, L .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 1999, 23 (03) :259-269
[5]   CYTOKINE PRODUCTION IN WHOLE-BLOOD EXVIVO [J].
FINCHARIETTA, MB ;
COCHRAN, FR .
AGENTS AND ACTIONS, 1991, 34 (1-2) :49-52
[6]   CONTRIBUTION OF COMPLEMENT-SYSTEM ON DESTABILIZATION OF LIPOSOMES COMPOSED OF HYDROGENATED EGG PHOSPHATIDYLCHOLINE IN RAT FRESH PLASMA [J].
FUNATO, K ;
YODA, R ;
KIWADA, H .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1103 (02) :198-204
[7]  
GENG Y, 1993, J IMMUNOL, V151, P6692
[8]   Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer [J].
Gordon, AN ;
Granai, CO ;
Rose, PG ;
Hainsworth, J ;
Lopez, A ;
Weissman, C ;
Rosales, R ;
Sharpington, T .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) :3093-3100
[9]  
GRAU GE, 1990, EUR CYTOKINE NETW, V11, P203
[10]   ADJUVANTS FOR HUMAN VACCINES - CURRENT STATUS, PROBLEMS AND FUTURE-PROSPECTS [J].
GUPTA, RK ;
SIBER, GR .
VACCINE, 1995, 13 (14) :1263-1276